Addressing Limited Treatment Options for Refractory CRC
The phase 2 INTERCEPT-TT trial showed that TAS-102 induced ctDNA clearance following adjuvant chemotherapy in patients with colorectal cancer.
Previous Post
KMC Manipal launches department of AI in healthcare
Next Post
Exclusive Breastfeeding Linked to Lower Risk of Central Precocious Puberty in Children: JAMA
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago